These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19241777)

  • 1. Are we doing enough to promote bone health in men with prostate cancer?
    Boyd LA
    Urol Nurs; 2008 Dec; 28(6):412-3. PubMed ID: 19241777
    [No Abstract]   [Full Text] [Related]  

  • 2. [Osteoporosis in castration therapy--a neglected field].
    Bratt O; Akesson K
    Lakartidningen; 2011 Sep 28-Oct 4; 108(39):1902-5. PubMed ID: 22111227
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevent and manage bone loss in men receiving androgen deprivation therapy.
    Becze E
    ONS Connect; 2010 Apr; 25(4):18-9. PubMed ID: 20437748
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR
    Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis after orchiectomy for prostate cancer.
    Daniell HW
    J Urol; 1997 Feb; 157(2):439-44. PubMed ID: 8996327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.
    Deng JH; Yang LP; Wang LS; Zhou DF
    Asian J Androl; 2004 Mar; 6(1):75-7. PubMed ID: 15064839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
    Ockrim JL; Lalani EN; Abel PD
    J Urol; 2005 May; 173(5):1829; author reply 1829-30. PubMed ID: 15821605
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
    Pitts WR
    J Urol; 2005 May; 173(5):1829; author reply 1829-30. PubMed ID: 15821604
    [No Abstract]   [Full Text] [Related]  

  • 10. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nursing implications of androgen deprivation therapy-associated bone loss.
    Weingard KK
    Urol Nurs; 2006 Aug; 26(4):261-9; quiz 270. PubMed ID: 16939043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of osteoporosis in men treated for prostate cancer.
    Oefelein MG; Resnick MI
    Urol Clin North Am; 2004 May; 31(2):313-9. PubMed ID: 15123410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer in older men.
    Calabrese DA
    Urol Nurs; 2004 Aug; 24(4):258-64, 268; quiz 269. PubMed ID: 15446376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive osteoporosis during androgen deprivation therapy for prostate cancer.
    Daniell HW; Dunn SR; Ferguson DW; Lomas G; Niazi Z; Stratte PT
    J Urol; 2000 Jan; 163(1):181-6. PubMed ID: 10604342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
    Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS; Ryan CW; Jung LL
    J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fracture risk in Danish men with prostate cancer: a nationwide register study.
    Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
    BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients.
    Moyad MA
    Urol Oncol; 2005; 23(1):56-64. PubMed ID: 15885584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of a long acting luteinizing hormone releasing hormone agonist (Decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Preliminary report.
    De Sy WA; de Meyer JM; Casselman J; De Smet R; Renders G; Schelfhout W; De Wilde P
    Acta Urol Belg; 1986; 54(2):221-9. PubMed ID: 2942015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.